Retrospective analysis of MCAMS-based anemia management showed an improvement in Hb maintenance within the target range (83% in 10 – 12.9 g/dL) and a 40% decrease in darbepoetin use. This evidence concerns the gene GSTM1 and anemia (phenotype).